A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER

Status: Recruiting
Location: See all (9) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

Eligibility
Participation Requirements
Sex: All
Minimum Age: 65
Healthy Volunteers: f
View:

∙ OLDER ADULTS WITH SIHD AND MCC

• Age ≥65 years

• ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)

• Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:

‣ positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease

⁃ coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or

‣ ≥50% stenosis of left main

⁃ Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89)

∙ CAREGIVERS

• Age ≥ 18 years

• Identified as caregiver of LIVEBETTER participant

Locations
United States
Connecticut
Yale School of Medicine
RECRUITING
New Haven
Georgia
Wellstar Research Institute
RECRUITING
Marietta
Illinois
Cook County Health
RECRUITING
Chicago
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
North Carolina
Duke University, School of Medicine
RECRUITING
Durham
New York
Mt. Sinai Health System
RECRUITING
New York
Nirvana Integrative Medicine
RECRUITING
New York
NYC Health and Hospitals, Harlem Hospital
NOT_YET_RECRUITING
New York
Virginia
Inova Health Care Services
RECRUITING
Fairfax
Contact Information
Primary
Michael Nanna, MD
livebetter-trial@yale.edu
(888) 683-0865
Time Frame
Start Date: 2023-05-10
Estimated Completion Date: 2027-05-30
Participants
Target number of participants: 741
Treatments
Experimental: Beta-Blockers (BB) Therapy
Participants randomized to this arm will be given a beta-blocker. Specific and appropriate drug selection from the class of beta blockers (i.e. type of BB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All BB will be administered orally (i.e. pills).
Experimental: Calcium Channel Blockers (CCB) Therapy
Participants randomized to this arm will be given a calcium channel blocker. Specific and appropriate drug selection from the class of calcium channel blockers (i.e. type of CCB, dosing, and escalation of dose) will be left to the site clinician in accordance with clinical guidelines. All CCB will be administered orally (i.e. pills).
Related Therapeutic Areas
Sponsors
Leads: Yale University

This content was sourced from clinicaltrials.gov